Purple Book reference family · 351(a) biologic
Rubella Virus Vaccine Live (MERUVAX II)
Rubella Virus Vaccine Live is an FDA-licensed reference biologic from Merck Sharp & Dohme LLC.
351(a) biologicBLA 101075 Merck Sharp & Dohme LLC
Biosimilars
0
Interchangeables
0
Listed patents
0
Reference approved
1969
Reference product
Originator biologic
351(a)BLA 101075
MERUVAX II Rubella Virus Vaccine Live
Merck Sharp & Dohme LLC
View full reference-product record- Approved
- Marketing
- Disc
- Center
- CBER
- Patents
- None listed
Exclusivity & patent cliffs
Protection horizon
Reference approval
Approval date of the reference Rubella Virus Vaccine Live product.
58 yr ago
Rubella Virus Vaccine Live: frequently asked questions
Reference exclusivity, biosimilars, interchangeability, and patents for this molecule, from the FDA Purple Book.
Built from official FDA Purple Book records (monthly downloads, the Advanced Search interface, and the published Patent List), with reference-product, license-type, and exclusivity context for Rubella Virus Vaccine Live.
Related FDA reference tools
- FDA Orange BookApproved drugs, generics, therapeutic-equivalence codes, patents, and exclusivity.
- FDA BiosimilarsFDA-approved biosimilars and interchangeable biosimilars, by reference product.
- 510(k) Predicate DatabaseSearch FDA 510(k) clearances and map predicate-device lineage.
- FDA 483 DatabaseFDA Form 483 observations and inspection records by firm, date, and citation.
